Book contents
- A Clinician’s Guide to Cannabinoid Science
- Reviews
- A Clinician’s Guide to Cannabinoid Science
- Copyright page
- Dedication
- Contents
- Preface
- Section 1 An Introduction to Cannabinoid Science
- Section 2 Potential Therapeutic Uses of Cannabinoids in Clinical Practice
- Chapter 6 Cannabinoids and Pain
- Chapter 7 Cannabinoids and Neuropsychiatry
- Chapter 8 Cannabinoids in Sleep and Circadian Rhythms
- Chapter 9 Cannabinoids and Inflammation and Autoimmune Disorders
- Chapter 10 Cannabinoids and the Eye
- Chapter 11 Cannabinoids and the Skin
- Index
- References
Chapter 6 - Cannabinoids and Pain
from Section 2 - Potential Therapeutic Uses of Cannabinoids in Clinical Practice
Published online by Cambridge University Press: 12 October 2020
Book contents
- A Clinician’s Guide to Cannabinoid Science
- Reviews
- A Clinician’s Guide to Cannabinoid Science
- Copyright page
- Dedication
- Contents
- Preface
- Section 1 An Introduction to Cannabinoid Science
- Section 2 Potential Therapeutic Uses of Cannabinoids in Clinical Practice
- Chapter 6 Cannabinoids and Pain
- Chapter 7 Cannabinoids and Neuropsychiatry
- Chapter 8 Cannabinoids in Sleep and Circadian Rhythms
- Chapter 9 Cannabinoids and Inflammation and Autoimmune Disorders
- Chapter 10 Cannabinoids and the Eye
- Chapter 11 Cannabinoids and the Skin
- Index
- References
Summary
In this chapter we will review selected preclinical and clinical studies that may lead to future development of cannabinoids as treatment for pain conditions. Although there are other therapeutic areas where cannabinoids potentially might one day be used, currently the only approvals of cannabinoid-based products have been medications that influence the central nervous system (CNS). Earlier we reviewed in Chapter 4 approvals for cannabinoid-based medicines from the US Food and Drug Administration (FDA), Canada Health and the European Medicines Agency (EMA) as well as other countries for indications that include pain.
- Type
- Chapter
- Information
- A Clinician's Guide to Cannabinoid Science , pp. 70 - 85Publisher: Cambridge University PressPrint publication year: 2020
References
Abrams, D. I. et al. (2007) ‘Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial’, Neurology, 68(7), 515–521. doi:10.1212/01.wnl.0000253187.66183.9c.Google Scholar
Aviram, J. and Samuelly-Leichtag, G. (2017) ‘Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials’, Pain Physician, 20(6), E755–E796.Google Scholar
Bachhuber, M. A. et al. (2014) ‘Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010’, JAMA Internal Medicine, 174(10), 1668–1673. doi:10.1001/jamainternmed.2014.4005.CrossRefGoogle Scholar
Baron, E. P. (2018) ‘Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and cannabis science’, Headache, 58(7), 1139–1186. doi:10.1111/head.13345.Google Scholar
Berlach, D. M., Shir, Y. and Ware, M. A. (2006) ‘Experience with the synthetic cannabinoid nabilone in chronic noncancer pain’, Pain Medicine, 7(1), pp. 25–29. doi:10.1111/j.1526-4637.2006.00085.x.CrossRefGoogle ScholarPubMed
Boehnke, K. A. et al. (2019) ‘Qualifying conditions of medical cannabis license holders in the United States’, Health Affairs, 38(2), 295–302. doi:10.1377/hlthaff.2018.05266.Google Scholar
Boes, C. J. (2015) ‘Osler on migraine’, Canadian Journal of Neurological Sciences, 42(2), 144–147. https://doi.org/10.1017/cjn.2015.6.Google Scholar
Bradford, A. C. and Bradford, W. D. (2017) ‘Medical marijuana laws may be associated with a decline in the number of prescriptions for medicaid enrollees’, Health Affairs, 36(5), 945–951. doi:10.1377/hlthaff.2016.1135.Google Scholar
Cooper, Z. et al. (2018) ‘Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability’, Neuropsychopharmacology, 43, 2046–2018. doi:10.1038/s41386-018-0011-2.Google Scholar
Cupini, L. M. et al. (2006) ‘Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs’, Cephalalgia, 26(3), 277–281. doi:10.1111/j.1468-2982.2005.01031.x.CrossRefGoogle Scholar
Cupini, L. M. et al. (2008) ‘Degradation of endocannabinoids in chronic migraine and medication overuse headache’, Neurobiology of Disease, 30(2), 186–189. doi:10.1016/j.nbd.2008.01.003.Google Scholar
Dorsey, S. G. and Morton, P. G. (2006) ‘HIV peripheral neuropathy: pathophysiology and clinical implications’, AACN Advanced Critical Care, 17(1), 30–36. doi:10.1097/00044067-200601000-00004.Google Scholar
Fallon, M. T. et al. (2017) ‘Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies’, British Journal of Pain, 11(3), 119–133. doi:10.1177/2049463717710042.Google Scholar
Finniss, D. G. et al. (2010) ‘Biological, clinical, and ethical advances of placebo effects’, The Lancet, 375(9715), 686–695. doi:10.1016/S0140-6736(09)61706-2.Google Scholar
Gaertner, J. and Schiessl, C. (2013) ‘Cancer pain management: what’s new?’, Current Pain and Headache Reports, 17(4), 328. doi:10.1007/s11916-013-0328-9.Google Scholar
Greco, R. et al. (2010) ‘The endocannabinoid system and migraine’, Experimental Neurology, 224(1), 85–91. doi:10.1016/j.expneurol.2010.03.029.Google Scholar
Greco, R. et al. (2018) ‘Endocannabinoid system and migraine pain: an update’, Frontiers in Neuroscience, 12,172. doi:10.3389/fnins.2018.00172.Google Scholar
Haroutounian, S. et al. (2016) ‘The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study’, Clinical Journal of Pain, 32(12), 1036–1043. doi:10.1097/AJP.0000000000000364.Google Scholar
Hefner, K., Sofuoglu, M. and Rosenheck, R. (2015) ‘Concomitant cannabis abuse/dependence in patients treated with opioids for non‐cancer pain’, American Journal of Addiction, 24(6), 538–545. doi:10.1111/ajad.12260.Google Scholar
Hoggart, B. et al. (2015) ‘A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain’, Journal of Neurology, 262(1), 27–40. doi:10.1007/s00415-014-7502-9.Google Scholar
Iqbal, Z. et al. (2018) ‘Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy’, Clinical Therapeutics, 40(6), 828–849. doi:10.1016/j.clinthera.2018.04.001.Google Scholar
Johnson, J. R. et al. (2010) ‘Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain’, Journal of Pain and Symptom Management, 39(2), 167–179. doi:10.1016/j.jpainsymman.2009.06.008.Google Scholar
Johnson, J. R. et al. (2013) ‘An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics’, Journal of Pain and Symptom Management, 46(2), 207–218. doi:10.1016/j.jpainsymman.2012.07.014.CrossRefGoogle ScholarPubMed
Lichtman, A. H. et al. (2018) ‘Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain’, Journal of Pain and Symptom Management, 55(2), 179.e1–188.e1. doi:10.1016/j.jpainsymman.2017.09.001.Google Scholar
Livingston, M. D. et al. (2017) ‘Recreational cannabis legalization and opioid-related deaths in Colorado, 2000-2015’, American Journal of Public Health, 107(11), 1827–1829. doi:10.2105/AJPH.2017.304059.Google Scholar
Lynch, M. E., Cesar-Rittenberg, P. and Hohmann, A. G. (2014) ‘A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain’, Journal of Pain and Symptom Management, 47(1), 166–173. doi:10.1016/j.jpainsymman.2013.02.018.Google Scholar
Lynch, M. E. and Ware, M. A. (2015) ‘Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials’, Journal of Neuroimmune Pharmacology, 10(2), 293–301. doi:10.1007/s11481-015-9600-6.Google Scholar
McGeeney, B. E. (2013) ‘Cannabinoids and hallucinogens for headache’, Headache, 53(3), 447–458. doi:10.1111/head.12025.Google Scholar
Mücke, M. et al. (2018) ‘Cannabis-based medicines for chronic neuropathic pain in adults’, Cochrane Database of Systematic Reviews, 3, CD012182. doi:10.1002/14651858.CD012182.pub2.Google Scholar
Narang, S. et al. (2008) ‘Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy’, The Journal of Pain, 9(3), 254–264. doi:10.1016/j.jpain.2007.10.018.Google Scholar
Nestler, E., Hyman, S. E. and Malenka, R. C. (eds.) (2001) Molecular Neuropharmacology. New York: McGraw-Hill.Google Scholar
Nielsen, S. et al. (2017) ‘Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis’, Neuropsychopharmacology, 42(9), 1752–1765. doi:10.1038/npp.2017.51.CrossRefGoogle ScholarPubMed
Nurmikko, T. J. et al. (2007) ‘Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial’, Pain, 133(1–3), 210–220. doi:10.1016/j.pain.2007.08.028.Google Scholar
Reynolds, J. R. (1890) ‘On the therapeutical uses and toxic effects of Cannabis indica’, The Lancet, 135(3473), 637–638. doi:10.1016/S0140-6736(02)18723-X.Google Scholar
Rhyne, D. N. et al. (2016) ‘Effects of medical marijuana on migraine headache frequency in an adult population’, Pharmacotherapy, 36(5), 505–510. doi:10.1002/phar.1673.Google Scholar
Rog, D. J. et al. (2005) ‘Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis’, Neurology, 65(6), 812–819. doi:10.1212/01.wnl.0000176753.45410.8b.CrossRefGoogle ScholarPubMed
Rossi, C. et al. (2008) ‘Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels’, European Journal of Clinical Pharmacology, 64(1), 1–8. doi:10.1007/s00228-007-0391-4.Google Scholar
Russo, E. B. (2016) ‘Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes’, Cannabis and Cannabinoid Research, 1(1), 154–165. doi:10.1089/can.2016.0009.Google Scholar
Ryan, T. (2019) ‘Osler Centenary Papers: Osler the clinician and scientist: a personal and historical perspective’, Postgraduate Medical Journal, 95(1130), 660–663. doi:10.1136/postgradmedj-2019-136645.Google Scholar
Sarchielli, P. et al. (2007) ‘Endocannabinoids in chronic migraine: CSF findings suggest a system failure’, Neuropsychopharmacology, 32(6), 1384–1390. doi:10.1038/sj.npp.1301246.Google Scholar
Shover, C. L. et al. (2019) ‘Association between medical cannabis laws and opioid overdose mortality has reversed over time’, Proceedings of the National Academy of Sciences of the United States of America, 116(26), 12624–12626. doi:10.1073/pnas.1903434116.Google Scholar
Svendsen, K. B., Jensen, T. S. and Bach, F. W. (2004) ‘Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial’, BMJ, 329(7460), 253. doi:10.1136/bmj.38149.566979.AE.Google Scholar
Toth, C. et al. (2012) ‘An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain’, Pain, 153(10), 2073–2082. doi:10.1016/j.pain.2012.06.024.Google Scholar
Verma, A. (2001) ‘Epidemiology and clinical features of HIV-1 associated neuropathies’, Journal of the Peripheral Nervous System, 6(1), 8–13. doi:10.1046/j.1529-8027.2001.006001008.x.Google Scholar
Ware, M. A. et al. (2010) ‘Smoked cannabis for chronic neuropathic pain: a randomized controlled trial’, CMAJ, 182(14), E694–E701. doi:10.1503/cmaj.091414.CrossRefGoogle ScholarPubMed
Ware, M. A. et al. (2015) ‘Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS)’, The Journal of Pain, 16(12), 1233–1242. doi:10.1016/j.jpain.2015.07.014.Google Scholar
Wen, H. and Hockenberry, J. M. (2018) ‘Association of medical and adult-use marijuana laws with opioid prescribing for medicaid enrollees’, JAMA Internal Medicine, 178(5), 673–679. doi:10.1001/jamainternmed.2018.1007.Google Scholar
Whiting, P. F. et al. (2015) ‘Cannabinoids for medical use: a systematic review and meta-analysis’, JAMA: Journal of the American Medical Association, 313(24), 2456–2473. doi:10.1001/jama.2015.6358.Google Scholar
Zajicek, J. et al. (2013) ‘Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial’, The Lancet Neurology, 12(9), 857–865. doi:10.1016/S1474-4422(13)70159-5.Google Scholar